Access to COVID-19 Vaccines and Medicines - a Global Public Good by Hein, Wolfgang & Paschke, Anne
www.ssoar.info
Access to COVID-19 Vaccines and Medicines - a
Global Public Good
Hein, Wolfgang; Paschke, Anne
Veröffentlichungsversion / Published Version
Arbeitspapier / working paper
Zur Verfügung gestellt in Kooperation mit / provided in cooperation with:
GIGA German Institute of Global and Area Studies
Empfohlene Zitierung / Suggested Citation:
Hein, W., & Paschke, A. (2020). Access to COVID-19 Vaccines and Medicines - a Global Public Good. (GIGA Focus
Global, 4). Hamburg: GIGA German Institute of Global and Area Studies - Leibniz-Institut für Globale und Regionale
Studien. https://nbn-resolving.org/urn:nbn:de:0168-ssoar-68332-2
Nutzungsbedingungen:
Dieser Text wird unter einer CC BY-ND Lizenz (Namensnennung-
Keine Bearbeitung) zur Verfügung gestellt. Nähere Auskünfte zu
den CC-Lizenzen finden Sie hier:
https://creativecommons.org/licenses/by-nd/3.0/deed.de
Terms of use:
This document is made available under a CC BY-ND Licence
(Attribution-NoDerivatives). For more Information see:
https://creativecommons.org/licenses/by-nd/3.0
Focus | Global              
Dr. Wolfgang Hein
Associate
wolfgang.hein@giga-hamburg.de
Anne Paschke
Research Fellow
anne.paschke@web.de
German Institute for Global and 
Area Studies (GIGA)
Leibniz-Institut für Globale  
und Regionale Studien
Neuer Jungfernstieg 21  
20354 Hamburg
www.giga-hamburg.de/giga-focus
Wolfgang Hein and Anne Paschke
Access to COVID-19 Vaccines and  
Medicines – a Global Public Good
GIGA Focus | Global | Number 4 | July 2020 | ISSN 1862-3581
New daily record numbers of infections worldwide exacerbate concerns 
about the impact of the COVID-19 pandemic on regions of the Global South. 
Weak health systems, vulnerable economies, and extreme inequalities 
threaten healthcare, livelihoods, and peace in many low- and middle-in-
come countries. The risk of increasing infection rates remains imminent for 
all countries until a vaccine or medicine is available to everyone worldwide.
 • While many low-income countries urgently need to “flatten the curve”, rigid 
lockdown measures are difficult to impose in the vast informal sector and can 
mean a more imminent threat to lives and livelihoods by depriving millions of 
income and food. 
 • COVID-19 has already led to a world economic crisis through the breakdown of 
trade and rapidly increasing debts, and will only aggravate global inequalities 
even further.
 • The key for slowing and eventually stopping the pandemic without lockdowns 
lies in the development of, and universal access to, effective drugs and vaccines, 
which are currently discussed on the highest political level as being “global 
public goods.” 
 • An unprecedented initiative vis-à-vis the required collective action in global 
health is the Access to COVID-19 Tools Accelerator bringing together many im-
portant stakeholders in global health. 
 • Whether stakeholders will meet their commitments on access is not clear yet, 
as a three-way conflict intensifies between those demanding access to health 
products as a global public good, pharmaceutical firms offering compromises 
but defending patent-based exclusive rights, and “vaccine nationalism” by in-
dividual states. 
Policy Implications
This pandemic could be an opportunity to realise access to vaccines and medi-
cines for all. The high-level public debate about medicines as a global public 
good is unprecedented, and there are promising examples of collective action. It 
remains to be seen whether national governments and pharmaceutical companies 
can be held accountable by the defenders of a global public good approach re-
garding their publicly voiced commitment to “access for all.”
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Pathway and Impact of the Pandemic in the Global South
Recognising the pandemic nature of COVID-19 has led to great concerns about the 
problems of poor countries in dealing with the disease. Potentially catastrophic im-
pacts are feared in particular in low- and a number of middle-income countries 
(lICs and MICs), with large groups of marginalised people in poor rural areas and 
urban slums. Other recent GIGA Foci have already highlighted the specific prob-
lems faced in Africa, latin America, and the Middle East as a result of the pandemic 
(see “Related GIGA Publications”).  It appears that food markets have been particu-
lar hubs of infection helping spread the virus in latin American countries (Collyns 
et al. 2020). The countries of the Arabian Peninsula are now among those with 
the highest rates of infections per one million inhabitants. However, this might be 
skewed because of their comparatively high rate of testing. At the same time they 
exhibit a comparatively low death rate due to their highly developed health systems. 
While sub-Saharan Africa was less severely hit until early April compared to other 
parts of the world, the pandemic has since started to gain pace there. There is also 
an imminent risk that COVID-19 will lead to more violent conflict on the continent, 
as basedau and Deitch (2020) outline.
by now, another hotspot of infection has developed in South Asia. India has 
586,956 confirmed infections and 17,417 deaths (as of  1 July), with 8,826,585 tests 
conducted (meaning only about 0.64 per cent of the population have been tested 
so far). A rigidly imposed lockdown, wearing of face masks in major Indian cities 
and many states being compulsory, and internal travel restrictions have resulted in 
reported hardships linked to these measures. The lockdown led to an exodus of mi-
grant workers desperately trying to reach their home villages. Kerala, on the other 
hand, is demonstrating that basic health system infrastructure and investments in 
human capital can make all the difference in controlling a pandemic even despite 
scarce resources: the state has a strong, highly decentralised public health system, 
clear risk communication, and effective community participation, all based on the 
enduring state welfare regime established by the Communist Party of India.
High rates of informal employment, weak health systems, and very limited test-
ing capacities are only some of the reasons why this pandemic represents a critical 
challenge for many lICs and lMICs. For example, while lombardy – a hard-hit region 
in Italy – had about 700 Intensive Care Unit beds for a population of 10.4 million 
people, Mali and burkina Faso have less than 20 ventilators for respective popula-
tions almost twice as large (Haas and Teachout 2020). According to an Organisation 
for Economic Co-operation and Development (OECD) study (2020a), about 86 per 
cent of total employment in Africa is informal and 82 per cent of the population are 
without social protection. Another critical aspect concerns food supplies; though a 
report of the Food and Agricultural Organization states that recent harvests have 
been good and the outlook for staple crops is promising, it warns of “indirect effects 
such as disruption of livelihoods, food supply chains and access to food, basic ser-
vices as well as humanitarian assistance” (2020: 6) – also affecting food supplies for 
the urban poor. The disruption of international trade affects the income of African 
exporters as well as the supply of essential imports.
The World Health Organization (WHO) regularly updates its guidance for coun-
tries on how to maintain essential health services in the face of the pandemic. De-
spite very different sociocultural and economic preconditions between the  Global 
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South and the Global North, the measures implemented in most high income coun-
tries (HICs) have been recommended as general coping mechanisms. 
Collateral Damage of Focusing All Efforts on COVID-19
However, more and more politicians from lICs have articulated that they are not in 
a position to afford a strict lockdown. For one, an economic lockdown can be a more 
imminent threat to lives and livelihoods by depriving millions of income and food. 
As protesting traders in Ghana put it: “They knew the lockdown was needed to curb 
the spread of the virus but they were not in a position to survive it” (Akinwotu and 
Asiedu 2020).
Furthermore, a complete lockdown might not be warranted in many lICs for 
other reasons besides. Cash and Patel point out that “for the first time in the post-
war history of epidemics, there is a reversal of which countries are most heavily 
affected by a disease pandemic” (2020: 1687). Many countries of the Global South 
exhibit a lower risk of COVID-19-related mortality since their populations are much 
younger. Since the beginning of the pandemic people in lICs and MICs have con-
tinued to die in the millions from numerous diseases that have been prevalent for 
much longer. For example, deaths among children under five from pneumonia in 
lICs and MICs were estimated at almost 900,000 for 2015 (McAllister et al. 2019). 
This number represents a reduction of 47 per cent during the Millennium Devel-
opment Goal period since the year 2000, which is consistent with a decreasing 
prevalence of risk factors and increasing socio-economic development, prevention, 
and improved access to quality healthcare. The strong focus on fighting COVID-19 
threatens to turn back the clock on years of progress and severely increase morbid-
ity and mortality for many diseases. Vaccination campaigns, for example, have been 
suspended in many countries, and the cessation of public transport has specifically 
prevented poor people as well as healthcare workers from reaching medical facili-
ties. For all these reasons, Cash and Patel (2020) emphasise that context is essential 
in controlling a pandemic and question the appropriateness of HIC strategies for 
peers with fewer resources.
Wealthier countries are now allegedly coming to the rescue of those less well-
endowed – not least to mitigate effects resulting from their “one-size-fits-all” lock-
down advice. At first sight, the international support announced by various in-
stitutions appears overwhelming. The G20 Action Plan (“Supporting the Global 
Economy Through the COVID-19 Pandemic”) presented on 15 April is the most 
comprehensive document of cooperation in the global fight against the  pandemic. 
G20 members agreed on a suspension of debt service payments for the poorest 
countries during 2020. The International Monetary Fund (IMF) has developed a 
crisis response package offering a USD 1 trillion lending capacity and the World 
Bank and Regional Development Banks are offering emergency response packages 
of more than USD 200 billion. For African countries already suffering from increas-
ing debt services in previous years this only means, however, a short-term easing of 
their foreign debt. In fact, by using the offered credits their foreign debt situation 
could become even more severe in the medium term.
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Impact of Lockdowns on the Global Economy and Growing 
Inequalities
Since April, it has been frequently stated that the world economy will suffer its 
worst year since the Great Depression of the 1930s. Many of the lockdown measures 
are expected to have a long-term negative impact on national economies, as well as 
the global one, due to reduced trade and decreasing income in many sectors. The 
OECD (2020b) estimates a reduction of activity in the main economies of between 
15 and 30 per cent of gross domestic product. Numerous countries will only be able 
to cope with the situation by incurring new foreign debts, which will not ease future 
development. The disruption of global value chains constitutes the potentially most 
significant impact on the structure of the world economy. 
Public compensation payments for the impact of lockdown measures are in-
tended to stabilise national economies, but they also adversely affect international 
competition. The payments – as seen particularly in European countries – have 
drawn criticism that they contribute to global inequalities, as stronger economies 
are in a better position to increase their competitiveness even further. Within the 
European union, COVID-19 has had a particularly strong impact on the economic 
situation in Italy and Spain. This has resulted in a heated discussion on an Eu re-
sponse to the crisis and the pathway to realising acts of solidarity. At first, medical 
assistance within the Eu came about very slowly. There has also been a long-run-
ning conflict over how to deal with the economic impact of the crisis – with some 
member countries opposing a “communitarisation of debts.”
If there are concerns about the aggravation of inequalities within the Eu, this 
applies even more so to the economic divide between HICs on the one side and 
LICs and some highly affected LMICs on the other. While emergency credits are 
offered by international financial Institutions on favourable conditions, they imply 
the increasing indebtedness of the hardest-hit countries. In combination with other 
economic and social dimensions, this is bound to only further exacerbate growing 
global inequalities.
The social and economic impacts are already severe, and the worrying outlook 
for the second half of 2020 is somehow uniting people and governments across the 
globe. The need for collective action “not only” for humanitarian reasons seems ob-
vious, and can present an opportunity for international collaboration never seen be-
fore. The key for slowing and eventually stopping the pandemic without economic 
lockdowns lies in the development of, and universal access to, effective drugs and 
vaccines. So far, international initiatives and developments give rise to cautious 
optimism. 
Access to Health Products for COVID-19 – a Global Public Good
At the launch of the Access to COVID-19 Tools (ACT) Accelerator (WHO 2020a) 
in April, the currently largest alliance to finance medicines and vaccine research, 
united Nations Secretary-General António Guterres and German chancellor Angela 
Merkel called potential vaccines and medicines clear examples of “global public 
goods” (GPGs). When taking their statement and the concept of GPGs at face value, 
this would mean that a future vaccine would need to be both non-excludable – that is, 
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universally available to everyone – and non-rival, as the immunisation of any per-
son is beneficial to everybody else. Since public goods are not born of market dy-
namics, their provision depends on collective action. This raises the questions of 
the motivation for financing provisions, and the mechanisms of allocating globally 
available resources.
The insufficient support to fight other global humanitarian crises (e.g. to pre-
vent major famines) makes collective action seem unlikely at first. At second glance, 
though, there might be a real opportunity at this point for pooling financial re-
sources and efforts on a global level. Indeed world leaders have united to make an 
unprecedented commitment to working together in order to accelerate access to 
COVID-19-related health products and tests for all (WHO 2020b). Since the begin-
ning of the pandemic there have been several international donor-pledging confer-
ences raising billions of euros for vaccines and medicines on each occasion. 
These commitments are a response to the severe impacts of the pandemic 
worldwide. The economic implications of fighting COVID-19 are not only devas-
tating for many countries on a national level, but also expected to create severe 
turbulence within the global economy. The longer there are no other ways than a 
“lockdown” to effectively control the pandemic – other than adopting the cynical 
attitude of not caring too much about the deaths of primarily the old –, the more 
serious and prolonged the economic consequences will be, and the higher the risk 
of violent political conflicts. 
Collective Action: Cooperation in Research and Development 
and Access to COVID-19 Health Products
Since March, global health governance impetuses have abounded in calls for co-
operation in research and development (R&D) and universal access to medicines. 
Based on the “R&D Blueprint for Action to Prevent Epidemics” established in 2015, 
an international group of scientists was invited to Geneva in February 2020 “to as-
sess the current level of knowledge about the new virus, agree on critical research 
questions that need to be answered urgently, and to find ways to work together to 
accelerate and fund priority research to curtail this outbreak and prepare for those 
in the future.”  In February 2020, the Coalition for Epidemic Preparedness Inno-
vation (CEPI, an initiative founded in Davos in 2017 by the governments of India 
and Norway), the bill & Melinda Gates Foundation, the Wellcome Trust, the World 
Economic Forum, and the World bank together launched a COVID-19 Vaccine De-
velopment Taskforce   (see Table 1 below for a timeline of selected actions and state-
ments by different stakeholders regarding access to COVID-19 tools). 
On 18 March, the WHO started the “Solidarity” clinical trial for COVID-19 
treatments with the participation of more than 100 member countries to compare 
four treatment options: remdesivir; lopinavir/ritonavir combined; lopinavir/rito-
navir combined with interferon-beta; and, hydroxychloroquine (or chloroquine). 
Eventually, on 24 April, the WHO launched the above-mentioned ACT Accelerator, 
which integrates most actors in the field of vaccine development and finance – such 
as CEPI, Gavi, the Vaccine Alliance, the Global Fund, unitaid, and the  International 
Federation of Pharmaceutical Manufacturers & Associations (IFPMA). The ACT 
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Accelerator mission statement implicitly includes self-criticism by some actors, in 
particular industry, regarding their positions in past conflicts, referring to the long 
process of securing access to HIV/AIDS medicines: “We remember lessons from the 
past, which have shown that even when effective tools are available to the world, too 
often some are protected, while others are not. This inequity is unacceptable – all 
tools to address COVID-19 must be available to all. In the fight against COVID-19, 
no one should be left behind” (WHO 2020a).
Table 1
Timeline showing se-
lected key actions of 
different stakeholders 
with regard to access 
to Covid-19 technolo-
gies
Source: authors’ com-
pilation.
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Collective Action Not Uncontested – Three-Way Conflict over 
Access to Medicines
Despite actors allegedly agreeing on the importance of equitable global access, 
there is a long-nursed conflict over access to medicines now clearly rearing its head 
amid abundant buzzwords like “GPGs,” “universal,” and “equitable.” We concep-
tualise this conflict as triangular (see Figure 1 below), with three major compet-
ing interests and stakeholder groups: (A) the pharmaceutical industry regarding 
patent-based exclusive rights; (b) certain nation states interested in securing health 
products first for themselves to speed up national recovery and (in some cases) to 
pursue hegemonic interests; and, (C) humanitarian, global, political, and economic 
interests to realise access to health products as GPGs. This latter interest is pursued 
by a diverse group of stakeholders, including patients, civil society organisations 
(CSOs), health workers, international organisations and foundations, and a number 
of lICs and MICs.
Although cooperation between multilateral institutions and transnational pharma-
ceutical corporations has been unusually broad with regards to the development of 
a COVID-19 vaccine, the distrust between CSOs and the pharmaceutical  industry 
remains deep-seated. While the normative pressure to work together towards 
 equitable access seems strong, CSOs fear that this putative common goal remains 
 merely paying lip service in the absence of actual binding commitments. In fact, 
critical CSOs expect “a new wave of pro-IP [Intellectual Property] proposals from 
industry in the wake of COVID-19”; so far, a binding R&D convention is not in sight. 
CSOs have released several open letters demanding access for all, and accounta-
bility mechanisms for access commitments (see Table 1 above for examples). uni-
versities allied for essential medicines (uAEM) found that most COVID-19 vaccine 
trials receive public funds and publishes a website that tracks whether COVID-19 
research so funded is indeed accessible to all.
Conflicts around patent applications for remdesivir (Gilead Sciences) have al-
ready emerged, alongside Sanofi’s alleged commitment to produce vaccines prior-
itising the united States market. On 28 May, IFPMA published their “Policy Prin-
ciples on COVID-19 Vaccines Initiative” – stressing the readiness of industry to 
support broad cooperation initiatives, but also insisting on supporting “expedite 
and effective product licensing approaches, recognizing that intellectual property 
has not been an impediment to pandemic response thus far” (2020).
Figure 1
Timeline with selected 
key actions of different 
stakeholders with 
regard to Access to 
COVID-19 technologies
Source: Authors.
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but also national interests have already come into play, casting doubt on the 
sincerity of the loudly voiced calls for equitable access. In June, several countries 
and GAVI struck deals with AstraZeneca for the supply of a potential vaccine that 
is currently being tested by the university of Oxford. France, Germany, Italy, and 
the Netherlands joined up to what has been labelled Europe’s Inclusive Vaccines 
Alliance (IVA). The multilateral deal is supposed to provide “equitable access to all 
participating countries across Europe” (AstraZeneca 2020). This shift in phrasing – 
adding “participating,” and replacing “worldwide” with “across Europe” – could give 
the discourse a new direction and be an indication of weak accountability regarding 
commitment to worldwide access. The CEO of CEPI referred to these national deals 
as “vaccine nationalism,” describing the phenomenon as the biggest barrier to eq-
uitable access to COVID-19 vaccines (Saldinger 2020). by the end of June, the uS 
government bought nearly all of Gilead Sciences’ production of remdesivir for July 
and 90 per cent of its August and September stocks too.
The language of the WHO’s WHA73 Resolution, sponsored by the EU and 
many other member countries, is equally telling. It uses strong wording on the 
right to health and calling for cooperation concerning intellectual property rights 
(IPRs) through existing mechanisms, for the voluntary pooling of patents and 
 licensing of medicines and vaccines (WHO, COVID-19 Response, Document A73/
CONF./1Rev.1). but it avoids any criticism on trade and IPR mechanisms, and falls 
short of suggesting concrete new solutions and binding commitments. Overall CSOs 
welcomed the draft, but stressed the need for more specific demands regarding 
transparency and the use of trade-related aspects of IPRs (TRIPS) flexibilities such 
as compulsory licensing – as exemplified in the Doha Declaration. Realising equita-
ble access for all will depend on whether or not effective accountability mechanisms 
are established. In their absence, it will be impossible to hold organisations, corpo-
rations, and governments to account.
What might raise hope is the growing impact of shareholder value in the phar-
maceutical industry; according to Reuters business News, a group of institutional 
investors – holding more than EuR 1.9 trillion in assets – published a statement 
calling on 15 major pharmaceutical companies “to set aside rivalries and short-term 
interests and cooperate on finding solutions to the coronavirus.” Their statement 
further reads: “Enforcing patents, excessive price setting, not disclosing relevant 
findings or securing extended market exclusivity through, for example, orphan drug 
designation should not run counter to this responsibility” (Sterling 2020). This im-
plies that the image of a company, stock prices, and its attractiveness for institu-
tional investors might (at least in the short and medium run) be economically more 
rewarding than profits from selling patented products at high prices. 
Will the GPG Be Delivered – and What After?
looking at past processes of creating universal access to medicines and vaccines, 
such as the vaccination campaign to eradicate smallpox, this has always taken a 
long period of time to achieve – usually decades. Will the urgency of controlling 
COVID-19 provide the necessary conditions for a more rapid realisation of  universal 
access (“no one left behind”)? 
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However the identified three-way conflict will play out, a core technical issue 
will make it difficult to achieve equal (meaning also, simultaneous) access to medi-
cines and vaccines for people all over the world: the sheer impossibility of  creating 
sufficient health products and providing the necessary medical infrastructure every-
where. The preconditions for a vaccination campaign include a cold chain for the 
storage and transport of dosages, as well as sterile needles and qualified health 
workers to administer them. Even though there have been many verbal commit-
ments vis-à-vis collective action in the controlling of COVID-19, global inequalities 
will be hard to overcome. It remains to be seen whether stakeholders will live up to 
their commitments in realising vaccination against COVID-19 as a GPG and even 
reform access to medicines in a sustainable way – or if the observed vaccine nation-
alism and strong industry lobby will cement existing structures that uphold access 
to medicines as a privilege only for those who can afford it. 
The severity and the all-encompassing nature of the COVID-19 crisis has led to 
the widespread conviction that it should be interpreted as an opportunity for a new 
start in global collective development. The point of departure here, however, is a 
paradox: on the one hand, it is seen as proof of the limits of globalisation, pointing 
to the impacts of the disruption of global value chains and an inward orientation 
among societies in fighting the disease; on the other, never before has there been a 
situation in which political discourses around the world have focused on almost the 
exact same political issues. Global discourses are dominated by the development of 
and access to COVID-19 vaccines and medicines, and by strategies to overcome the 
economic crisis – all heavily dependent on global cooperation. 
Despite the urgent hope and indeed need for COVID-19 medicines and vaccines, 
Kohler and Mackey (2020) warn against bypassing existing regulatory safeguards 
in favour of earlier access to immature and possibly unsafe products. They also call 
for delegating responsibility to a supranational body that can establish a system 
to coordinate rational selection, procurement, access, and distribution across all 
countries. If the global community succeeds in overcoming national protectionism 
impulses and focuses rather on protecting people’s rights to equitable access in-
stead of industry’s rights to patents, the current pandemic could be a game changer 
for access to medicines.
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